Lemay A

No ORCID on file · 38 papers in corpus
article 1990
A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 Study Group.
Progress in clinical and biological research
1989
Intranasal LHRH agonist combined periodically with a progestogen for contraception.
Advances in contraception : the official journal of the Society for the Advancement of Contraception ·doi:10.1007/bf01890898
article 1989
Long-Term Use of the Low Dose LHRH Analogue Combined With Monthly Medroxy-Progesterone Administration
Hormone research ·doi:10.1159/000181330

In a pilot study, chronic pelvic pain associated with endometriosis, dysmenorrhoea or menorrhagia has been treated for prolonged periods with low dose buserelin (daily) and medroxy-progesterone (monthly). The partial inhibition of ovarian f…

article 1988
Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis
American journal of obstetrics and gynecology ·doi:10.1016/0002-9378(88)90128-7

We have previously reported reversible hypogonadism induced by the intranasal administration of the luteinizing hormone-releasing hormone agonist buserelin as a new therapeutic approach for endometriosis. Thirteen patients were randomized t…

article 1988
Escape from the down-regulation of the pituitary-ovarian axis following decreased infusion of luteinizing hormone-releasing hormone agonist
Fertility and sterility ·doi:10.1016/s0015-0282(16)59887-2

In order to suppress the pituitary-ovarian axis for treatment of endometriosis, the luteinizing hormone-releasing hormone (LH-RH) agonist buserelin (Hoechst Canada Inc., Montreal, Quebec, Canada) was administered by continuous subcutaneous …

article 1988
Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase
Fertility and sterility ·doi:10.1016/s0015-0282(16)59764-7

Six endometriosis patients were treated with continuous subcutaneous (SC) infusion of a luteinizing hormone-releasing hormone (LH-RH) agonist using an external osmotic minipump system. Serum estradiol (E2) was suppressed into the menopausal…

article 1987
LH-RH agonist treatment of endometriosis.
Contributions to gynecology and obstetrics
article 1987
Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases
Fertility and sterility ·doi:10.1016/s0015-0282(16)59281-4
article 1986
Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
Progress in clinical and biological research
article 1986
Round table discussion of endometriosis and its treatment.
Progress in clinical and biological research
case-report 1984
Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report
Fertility and sterility ·doi:10.1016/s0015-0282(16)48152-5
other 1984
Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis
Fertility and sterility ·doi:10.1016/s0015-0282(16)47899-4

Ten women with endometriosis (stages I to IV) were treated with twice-daily subcutaneous injections of 200 micrograms of (D-Ser[TBU]6-des-Gly-NH2(10] luteinizing hormone-releasing hormone ethylamide (Buserelin) for 5 days followed by 400 mi…

article 1982
Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist
Fertility and sterility ·doi:10.1016/s0015-0282(16)46522-2